Anti-Asialo GM1 NK Cell Depleting Antibody Does Not Alter the Development of Bleomycin Induced Pulmonary Fibrosis
暂无分享,去创建一个
[1] R. Welsh,et al. Therapeutic Depletion of Natural Killer Cells Controls Persistent Infection , 2013, Journal of Virology.
[2] Lianfeng Zhang,et al. Transgenic expression of IL-33 activates CD8(+) T cells and NK cells and inhibits tumor growth and metastasis in mice. , 2013, Cancer letters.
[3] Z. Tian,et al. Natural killer cells in liver disease , 2013, Hepatology.
[4] K. Kane,et al. NK cells exacerbate the pathology of influenza virus infection in mice , 2013, European journal of immunology.
[5] W. Ouyang,et al. IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection , 2012, Mucosal Immunology.
[6] J. Ledford,et al. Surfactant protein-D regulates effector cell function and fibrotic lung remodeling in response to bleomycin injury. , 2012, American journal of respiratory and critical care medicine.
[7] C. Trautwein,et al. The chemokine receptor CXCR3 limits injury after acute toxic liver damage , 2012, Laboratory Investigation.
[8] K. Schwarz,et al. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. , 2011, Blood.
[9] Thomas A. Wynn,et al. Integrating mechanisms of pulmonary fibrosis , 2011, The Journal of experimental medicine.
[10] H. Karasuyama,et al. NK Cell-Depleting Anti-Asialo GM1 Antibody Exhibits a Lethal Off-Target Effect on Basophils In Vivo , 2011, The Journal of Immunology.
[11] M. Gunn,et al. Recruited exudative macrophages selectively produce CXCL10 after noninfectious lung injury. , 2011, American journal of respiratory cell and molecular biology.
[12] E. Casanova,et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. , 2011, Blood.
[13] R. Homer,et al. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. , 2010, The Journal of clinical investigation.
[14] T. Wynn,et al. Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent , 2010, The Journal of experimental medicine.
[15] M. Jordana,et al. Influenza Infection Leads to Increased Susceptibility to Subsequent Bacterial Superinfection by Impairing NK Cell Responses in the Lung , 2010, The Journal of Immunology.
[16] F. Culley. Natural killer cells in infection and inflammation of the lung , 2009, Immunology.
[17] B. Gao,et al. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases , 2009, Journal of leukocyte biology.
[18] S. Sahn,et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.
[19] C. Hogaboam,et al. Murine models of pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.
[20] M. Fujimoto,et al. E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosis. , 2006, The American journal of pathology.
[21] S. Friedman,et al. Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC. , 2006, Journal of hepatology.
[22] R. Sun,et al. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. , 2006, Gastroenterology.
[23] W. Park,et al. Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. , 2005, The American journal of pathology.
[24] M. Burdick,et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. , 2005, American journal of respiratory and critical care medicine.
[25] W. Park,et al. Natural killer T (NKT) cells attenuate bleomycin-induced pulmonary fibrosis by producing interferon-gamma. , 2005, The American journal of pathology.
[26] A. Tominaga,et al. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. , 2004, DNA and cell biology.
[27] R. Homer,et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.
[28] Hideo Sakamoto,et al. Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. , 2004, American journal of respiratory cell and molecular biology.
[29] G. Izbicki,et al. Role of interferon-γ in the evolution of murine bleomycin lung fibrosis , 2003 .
[30] G. Izbicki,et al. Role of interferon-gamma in the evolution of murine bleomycin lung fibrosis. , 2003, American journal of physiology. Lung cellular and molecular physiology.
[31] K. Koyama. NK1.1+ cell depletion in vivo fails to prevent protection against infection with the murine nematode parasite Trichuris muris , 2002, Parasite immunology.
[32] M. Zöller,et al. Donor T cell and host NK depletion improve the therapeutic efficacy of allogeneic bone marrow cell reconstitution in the nonmyeloablatively conditioned tumor‐bearing host , 2002, Journal of leukocyte biology.
[33] A. Pardo,et al. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy , 2001, Annals of Internal Medicine.
[34] M. Wills-Karp,et al. Attenuation of lung inflammation and fibrosis in interferon-gamma-deficient mice after intratracheal bleomycin. , 2001, American journal of respiratory cell and molecular biology.
[35] J. Whitton,et al. NK Markers Are Expressed on a High Percentage of Virus-Specific CD8+ and CD4+ T Cells1 , 2000, The Journal of Immunology.
[36] American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). , 2000, American journal of respiratory and critical care medicine.
[37] David A. Lynch,et al. Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .
[38] C. Larsen,et al. Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection. , 1999, The Journal of clinical investigation.
[39] J M Simpson,et al. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. , 1988, Journal of clinical pathology.
[40] R. Crystal,et al. Familial idiopathic pulmonary fibrosis. Evidence of lung inflammation in unaffected family members. , 1986, The New England journal of medicine.
[41] J Stein-Streilein,et al. In vivo treatment of mice and hamsters with antibodies to asialo GM1 increases morbidity and mortality to pulmonary influenza infection. , 1986, Journal of immunology.
[42] A. Santoni,et al. Reactivity of Anti‐Asialo GM1 Serum With Tumoricidal and Non‐Tumoricidal Mouse Macrophages , 1985, Journal of leukocyte biology.
[43] M. Kasai,et al. A glycolipid on the surface of mouse natural killer cells , 1980, European journal of immunology.